The agreement will cover technology transfer, scale-up, and validation of the manufacturing process for TNFerade through cGMP consistency lots that will be produced at Cobra’s facility in Oxford, UK. GenVec is developing TNFerade for use in combination with radiation and chemotherapy for the treatment of various cancers.
Bryan Butman, senior vice president of Vector Operations at GenVec, said: “Activities under this agreement will establish a clear path for the submission of the chemistry, manufacturing, and controls (CMC) portion of a biological license application for TNFerade as GenVec works towards the completion of our current Phase III clinical trial.”